Clinical Research Studies in Hoag Neurosciences Institute
Participation in research and clinical investigation is an important commitment
of Hoag Neurosciences Institute in its mission to provide patients access
to leading-edge management and treatment for neurological disorders.
Hoag’s sub-specialized team of neuroscientists are actively involved
in research to discover new therapies, drugs and other medical advancements
to better the lives of patients suffering from neurological conditions.
Hoag Neurosciences Institute is currently accepting patients to participate
in a number of clinical research trials.
Please contact Laura Whitaker, RN (949-764-8190 or
firstname.lastname@example.org) or Channy Mai (949-764-8191 or
Channy.email@example.com) to learn more about each protocol and whether you may qualify. Your participation
in any trial is entirely voluntary. You may decide to withdraw at any
time without losing the benefits of your standard medical care.
Clinical Research Studies for Brain Tumors
DC-Vax®-L for Glioblastoma (GBM)
Principal Investigator: Christopher Duma, MD, FACS
This randomized Phase III trial research trial is designed to evaluate
the safety, clinical response and survival of patients following treatment
with DCVax®-L, an immunotherapy treatment for patients with newly-diagnosed
Glioblastoma Multiforme (also know as Glioblastoma, GBM and Grade IV Astrocytoma).
This experimental therapy uses a patient's own tumor and white blood
cells to create a patient-specific vaccine intended to "teach"
the immune system how to recognize brain cancer cells.
Key to this study is that patients must begin study screening at Hoag Hospital
Newport Beach before surgery to remove the tumor. DCVax®-L cannot
be prepared from preserved tumor tissue. Study patients will receive standard of care treatment for GBM, including
radiation and Temodar therapy, and two out of three will additionally
receive DCVax®-L, with the remaining one-third receiving a placebo.
Patients randomized to receive placebo will have the option to receive
DCVax®-L in a crossover arm upon documented disease progression. (Note:
DCVax®-L when used for patients with brain cancer is sometimes also
referred to as DCVax®-Brain.)
Please contact Robin Ellis, RN, at 949-764-5543 or
firstname.lastname@example.org to learn more. Additional information is also available at
Clinical Research Studies for Stroke
Clinical Research Studies for Alzheimer’s Disease